Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20797535 | 1.00 | KCNJ1 (0.46) | KCNJ1CNR2KDM4ECNR1ALDH1A1 | |
| SCHEMBL20810916 | 1.00 | KCNJ1 (0.46) | KCNJ1CNR2KDM4ECNR1ALDH1A1 | |
| SCHEMBL20797611 | 1.00 | KCNJ1 (0.46) | KCNJ1CNR2KDM4ECNR1ALDH1A1 | |
| SCHEMBL20797677 | 0.92 | KCNJ1 (0.47) | KCNJ1CNR2KDM4EALDH1A1KMT2A | |
| SCHEMBL20797376 | 0.83 | KCNJ1 (0.43) | KCNJ1CNR2KDM4EALDH1A1KMT2A | |
| SCHEMBL20810990 | 0.81 | KCNJ1 (0.44) | KCNJ1KDM4EMAPT | |
| SCHEMBL20797592 | 0.78 | KCNJ1 (0.42) | KCNJ1 | |
| SCHEMBL20798380 | 0.78 | KCNJ1 (0.42) | KCNJ1 | |
| SCHEMBL8435280 | 0.75 | CNR2 (0.47) | CNR2KDM4ECNR1ALDH1A1MYC | |
| SCHEMBL20692500 | 0.73 | HDAC1 (0.46) | KCNJ1CNR2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019049061-A1 | 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-03-14 | — | — | WO | disclosed |